Clal Biotechnology Industries Ltd. (TASE:CBI) announced that it has entered into an investment agreement for private placement of 6,024,180 common shares at ILS 3.32 per share for gross proceeds of ILS 20,000,277.6 on April 9, 2017. The transaction will include participation from Yelin Lapidot Provident Funds Management Ltd. for 2,108,460 shares and 2,610,480 warrants and Yelin Lapidot - Mutual Funds Management Ltd. for 3,915,720 shares and 2,610,480 warrants. The investors will acquire 4% stake in the company. The warrants are exercisable at ILS 3.70 per share for a period of within 18 months and ILS 4 per share between 18 and 24 months. The securities issued are subject to hold period of six months from the date of issue. The transaction is subject to Tel Aviv Stock Exchange approval for listing.